BGI said last week that it is conducting RNA-seq studies in 500 neuroblastoma samples to show the technique's ability to predict patient outcomes as part of the US Food and Drug Administration's Sequencing Quality Control Project.
SEQC is the third phase of the MicroArray Quality Control project and aims to assess the technical performance of next-generation sequencing platforms for RNA and DNA analyses.
BGI said that it will perform the library construction, sequencing, and bioinformatics analysis for the 500 neuroblastoma samples. The results will be compared to microarray data.
The University Children's Hospital of Cologne is collaborating with BGI on the project. "While we have built predictive models for neuroblastoma patients with microarray data, some of those still need to be improved," Matthias Fischer, a researcher at the university, said in a statement.
Compared to microarrays, RNA-seq data could be utilized to "better understand human transcriptomics and identify functional genetic variants associated with disease and drug risks," he added.